Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pharmacogenetic studies in depression: a proposal for methodologic guidelines.

A Serretti1, M Kato, J L Kennedy

  • 1Institute of Psychiatry, University of Bologna, Bologna, Italy. alessandro.serretti@unibo.it

The Pharmacogenomics Journal
|August 9, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A stratified treatment algorithm in psychiatry: a program on stratified pharmacogenomics in severe mental illness (Psych-STRATA): concept, objectives and methodologies of a multidisciplinary project funded by Horizon Europe.

European archives of psychiatry and clinical neuroscience·2024
Same author

North Eastern Iowa Veterinary Medical Association.

The Journal of comparative medicine and veterinary archives·2022
Same author

Influence of BDNF Val66Met polymorphism on excitatory-inhibitory balance and plasticity in human motor cortex.

Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology·2021
Same author

Clinical factors predicting treatment resistant depression: affirmative results from the European multicenter study.

Acta psychiatrica Scandinavica·2018
Same author

Clinical correlates of augmentation/combination treatment strategies in major depressive disorder.

Acta psychiatrica Scandinavica·2018
Same author

Erratum for Kennedy et al., "Genome Sequences of Three Novel Isolates of Human Parainfluenza Virus 2 Associated with Acute Respiratory Infection".

Genome announcements·2017
Same journal

Toxicity related to immunotherapy in urothelial cancer: Tumour genetic risk variants.

The pharmacogenomics journal·2026
Same journal

Beyond the 'Pregnancy Black Box': a global roadmap for artificial intelligence-driven pharmacogenomics in maternal-neonatal health.

The pharmacogenomics journal·2026
Same journal

The association of ABCB1, CYP2C19 and CYP2C9 combined activity with clopidogrel resistance in patients with recurrent ischemic stroke.

The pharmacogenomics journal·2026
Same journal

Development and validation of an open data model for pharmacogenetics to enable semantic interoperability in clinical practice.

The pharmacogenomics journal·2026
Same journal

Finasteride, pharmacogenomics, and suicide risk: a public health concern.

The pharmacogenomics journal·2026
Same journal

Cost-effectiveness of genome-guided statin treatment for hypercholesterolemia.

The pharmacogenomics journal·2026
See all related articles

Pharmacogenetic research in mood disorders faces challenges due to varied methods. Establishing standardized guidelines is crucial for reliable gene-environment interaction findings in treatment outcomes.

Area of Science:

  • Psychiatry
  • Genetics
  • Pharmacology

Background:

  • Pharmacogenetic studies linking gene variants to mood disorder treatment outcomes are increasing.
  • Methodological heterogeneity across studies hinders result comparison and limits generalizability.

Purpose of the Study:

  • To review the current state of pharmacogenetic study methodologies in mood disorders.
  • To propose guidelines for future pharmacogenetic research to enhance reliability and comparability.

Main Methods:

  • Literature review of existing pharmacogenetic studies in mood disorders.
  • Analysis of methodological variations and their impact on study findings.

Main Results:

  • Significant variability exists in sampling, diagnostics, treatment standardization, compliance monitoring, observation duration, response criteria, and environmental factor assessment.

Related Experiment Videos

  • These inconsistencies impede the synthesis of reliable findings in the field.

    • Conclusions:

    • Standardized methodologies are essential for robust pharmacogenetic research in mood disorders.
    • Adherence to proposed guidelines will improve the validity and clinical utility of pharmacogenetic findings.